SUPPORT

ELIGARD should not be used by anyone who is allergic to any drug product in the same class of products, or who is allergic to any of the ingredients of Eligard, including leuprolide acetate. Life-threatening allergic reactions have been reported with the drugs in Eligard’s class . Eligard should not be used in women who are pregnant of may become pregnant. ELIGARD can cause pregnancy loss and harm to the fetus when used by a pregnant woman.

Eligard, like other drugs in its class, causes a temporary increase in testosterone during the first and second weeks of treatment. Patients may experience worsening of symptoms or new symptoms during the first weeks of treatment, including bone pain, nerve damage, blood in the urine, pressure on the spine, or difficulty urinating. If your cancer has spread to the spine or urinary tract, urinary blockage or pressure in the spine may occur and can sometimes lead to paralysis, which may be fatal. You may require close medical attention during the first few weeks of therapy and you should notify your doctor if you develop any new or worsened symptoms after beginning treatment with Eligard.

Elevated blood sugar and an increased risk of developing diabetes have been reported in men receiving the drugs in Eligard’s class. Your doctor will monitor your blood sugar levels. Increased risk of heart attack, sudden death due to heart attack, and stroke has also been reported in men with the use of the drugs in Eligard’s class. Your doctor will monitor you for heart disease.

The most common injection site side effects are temporary burning and stinging, pain, bruising and redness. The most common systemic adverse events include mild to severe hot flashes/sweats, fatigue, weakness, muscle pain, dizziness, clamminess, testicular shrinkage and breast enlargement. For more information on these and other side effects, please talk to your doctor.

Click here for full Prescribing Information and full mixing and administration instructions.